ASTIN: a Bayesian adaptive dose-response trial in acute stroke.

Area of Science:

• Pharmacology and Drug Development
• Clinical Trial Design
• Neuroprotection

Background:

• Understanding drug dose-response relationships is crucial for successful pharmaceutical development.
• Efficiently determining the effective dose, specifically the ED95 (the dose producing 95% of the maximal effect), is a key challenge.
• Adaptive trial designs offer potential improvements over traditional methods.

Purpose of the Study:

• To describe and evaluate an adaptive trial design for efficiently learning about dose-response relationships and the ED95.
• To incorporate dynamic rules for early trial termination based on efficacy or futility.
• To report on the application of this design in a clinical setting.

Main Methods:

• An adaptive trial design incorporating a dynamic termination rule for early stopping was developed.
• The design was implemented in the ASTIN trial, a phase II proof-of-concept study.
• The study focused on the neuroprotectant neutrophil inhibitory factor (NIF) for acute stroke treatment.

Main Results:

• The adaptive design facilitated efficient learning about the dose-response of NIF.
• The dynamic termination rule allowed for timely decisions regarding trial continuation or discontinuation.
• The trial provided practical insights into the deployment of such adaptive designs.

Conclusions:

• Adaptive designs with dynamic termination rules can enhance the efficiency of dose-response studies in drug development.
• The ASTIN trial demonstrated the feasibility and utility of this adaptive approach in a neuroprotection context.
• Learning from this trial can inform future adaptive clinical trial designs for neurological conditions.